A Deeper Look into PARP Inhibitors in the Management of Ovarian, Breast and Prostate Cancers: Individualizing Treatment for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

PARP Inhibition and its Evolving Use in the Treatment of Cancers: What Managed Care Needs to Know for Improved Clinical and Economic Outcomes is a 3-part live webinar series that will provide attendees with the latest information in PARP Inhibitors

This is Part 2 of the series focusing on the management and individualizing treatment with PARP inhibitors
Click Here to view all 3 parts in this series 

This activity is an archive from the webinar held January 16, 2019

This activity is valid from February 15, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
AstraZeneca

Description:
A new class of targeted agents known as poly (ADP-ribose) polymerase (PARP) inhibitors have shown improved efficacy and are leading the way in the treatment of breast, ovarian and prostate cancers. In addition, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. This enzyme, known as PARP, is a critical component of DNA base excision repair, essential for the repair of single-strand breaks in DNA. If the action of PARP is inhibited in a normal cell, these breaks are converted to double-strand breaks and repaired through the process of homologous recombination. However, in cells with pre-existing defects in the homologous recombination DNA repair pathway, such as in cancer cells harboring BRCA1/2 mutations, inhibition of PARP results in synthetic lethality. Exploitation of this deficiency with PARP inhibitors create a therapeutic opportunity for tumor cell-specific cell killing. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in several cancers include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.

Upon completion of this activity, participants will be able to:

  • Explain tumor biology mechanisms that provide the rationale for targeting PARP in the treatment of cancers

  • Explore the role of PARP inhibitors in the current oncology treatment landscape including ovarian, breast and prostate cancer

  • Compare PARP inhibitors in cancer therapy including mechanisms of action, delivery methods, dosing and scheduling, efficacy, safety, interactions, and ease of use

  • Analyze the role of genetic testing and biomarkers for the identification of patients with various cancers to be treated with PARP inhibition, including those with BRCA-mutated disease
     

Faculty: Don S. Dizon, MD, FACP, FASCO
Director, Women’s Cancers, Lifespan Cancer Institute
Director of Medical Oncology, Rhode Island Hospital
Associate Professor of Medicine, Alpert Medical School of Brown University

Disclosure:

Dr. Dizon has no real or perceived financial relationships to disclose His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
AstraZeneca

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue